Zavegepant

DRUG9 trials

Sponsors

Pfizer, Mayo Clinic, Icahn School of Medicine at Mount Sinai, University of South Florida

Conditions

Acute MigraineAcute Treatment of MigraineAsthmaHealthyMigraineMigraine DiseaseMigraine HeadacheMigraine Headaches

Phase 1

Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma

TerminatedNCT04987944

Start: 2021-10-18End: 2023-04-04Updated: 2024-07-19

A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants

CompletedNCT05960032

Start: 2023-10-23End: 2023-12-12Updated: 2025-01-06

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

RecruitingNCT06995729

PfizerAcute Treatment of Migraine

Start: 2025-05-16End: 2027-08-12Target: 16Updated: 2026-03-18

A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

Not yet recruitingNCT07667621

University of South FloridaAcute Migraine, Migraine, Migraine Disease +4

Start: 2026-07-01End: 2027-08-01Target: 100Updated: 2026-06-25

Phase 2

Acute Treatment Trial in Adult Subjects With Migraines

CompletedNCT03872453

Start: 2019-03-25End: 2019-11-11Updated: 2023-09-25

Phase 3

Randomized Trial in Adult Participants With Acute Migraines

CompletedNCT04571060

Start: 2020-10-27End: 2021-10-22Updated: 2023-04-24

A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

CompletedNCT05989048

Start: 2023-11-29End: 2025-05-30Updated: 2026-05-22

Phase 4

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

RecruitingNCT06401642

Mayo ClinicMigraine

Start: 2024-03-22End: 2027-03-01Target: 200Updated: 2026-09-17

Acute Migraine Treatment in the ED With Gepants

TerminatedNCT06985342

Icahn School of Medicine at Mount SinaiMigraine Headaches

Start: 2025-06-05End: 2026-02-04Updated: 2026-04-29

Related Papers

Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial.

2025-01-021 citations

Zavegepant 10 mg Nasal Spray is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials (S47.003)

Neurology2023-04-252 citations

Zavegepant Nasal Spray for the Acute Treatment of Migraine With Aura and Without Aura: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials (S47.004)

Neurology2023-04-251 citations

Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial (PL5.002)

Neurology2023-04-25

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.

2023-03-0195 citations

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial

Headache The Journal of Head and Face Pain2022-10-0195 citations